TARSUS PHARMACEUTICALS, INC.: net inventory
Net inventory for TARSUS PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All TARSUS PHARMACEUTICALS, INC. financial histories
What this measure means
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
Exact concept: us-gaap:InventoryNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2022-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 4,372,000 | USD | 2026-02-23 | 10-K · 0001819790-26-000019 |
| At date | 2024-12-31 | 2,620,000 | USD | 2026-02-23 | 10-K · 0001819790-26-000019 |
| At date | 2023-12-31 | 3,107,000 | USD | 2025-02-25 | 10-K · 0001819790-25-000011 |
| At date | 2022-12-31 | 0 | USD | 2024-02-27 | 10-K · 0001819790-24-000018 |
Related financial histories
- TARSUS PHARMACEUTICALS, INC.: total assets
- TARSUS PHARMACEUTICALS, INC.: total liabilities
- TARSUS PHARMACEUTICALS, INC.: stockholders equity
- TARSUS PHARMACEUTICALS, INC.: cash and cash equivalents
- TARSUS PHARMACEUTICALS, INC.: net income or loss
- TARSUS PHARMACEUTICALS, INC.: operating cash flow
- TARSUS PHARMACEUTICALS, INC.: capital expenditure payments
- TARSUS PHARMACEUTICALS, INC.: revenue
- TARSUS PHARMACEUTICALS, INC.: financing cash flow
- TARSUS PHARMACEUTICALS, INC.: investing cash flow
- TARSUS PHARMACEUTICALS, INC.: retained earnings or deficit
- TARSUS PHARMACEUTICALS, INC.: basic weighted-average shares
- TARSUS PHARMACEUTICALS, INC.: diluted weighted-average shares
- TARSUS PHARMACEUTICALS, INC.: basic earnings per share
- TARSUS PHARMACEUTICALS, INC.: diluted earnings per share
- TARSUS PHARMACEUTICALS, INC.: income tax expense or benefit
- TARSUS PHARMACEUTICALS, INC.: net property, plant and equipment
- TARSUS PHARMACEUTICALS, INC.: share-based compensation expense
- TARSUS PHARMACEUTICALS, INC.: operating income or loss
- TARSUS PHARMACEUTICALS, INC.: current assets
- TARSUS PHARMACEUTICALS, INC.: interest expense
- TARSUS PHARMACEUTICALS, INC.: current liabilities
- TARSUS PHARMACEUTICALS, INC.: net finite-lived intangible assets
- TARSUS PHARMACEUTICALS, INC.: net current accounts receivable
- TARSUS PHARMACEUTICALS, INC.: operating expenses
- TARSUS PHARMACEUTICALS, INC.: selling, general and administrative expense
- TARSUS PHARMACEUTICALS, INC.: research and development expense
Inspect the source
- Entity
- TARSUS PHARMACEUTICALS, INC. / CIK 0001819790
- Captured
- 2026-09-21T17:34:53.927Z
- SEC response SHA-256
f995030f14e1a5328df4d6a202c57fcdcacbd3b769990e2aab0170d7476412a1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001819790.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))